Tesofensine Capsules

TheraTide USA

$119.19
Availability:
In Stock
Adding to cart… The item has been added

Product Overview

Compound: Tesofensine—a triple monoamine reuptake inhibitor (serotonin, norepinephrine, dopamine).

Form: Capsules; US-made research-grade purity ≥ 98%. Suitable for pharmacological and metabolic studies.

For laboratory research use only—NOT intended for human or veterinary application.

Batch-tested purity ≥98%. Certificate available on request—email providers@theratideusa.com.

  • Appetite & Metabolism: In obese rat models, tesofensine suppresses appetite by inhibiting lateral hypothalamus GABAergic neurons, extending weight loss effects and preventing rebound :contentReference[oaicite:1]{index=1}.
  • Clinical Weight Loss: In Phase II human trials (TIPO‑1), 0.5 mg/d yielded 9–10.6% weight loss over 24 weeks—about twice placebo; 0.5 mg group lost ~13–14 kg over 48 weeks in the extension TIPO‑4 trial :contentReference[oaicite:2]{index=2}.
  • Mechanism of Action: Selectively inhibits serotonin (IC₅₀ ~11 nM), norepinephrine (~1.7 nM), and dopamine (~65 nM) transporters, decreasing appetite while moderately increasing energy expenditure :contentReference[oaicite:3]{index=3}.
  • Safety Profile: Common side effects include dry mouth, nausea, constipation, insomnia; slight increase in heart rate (≈7 bpm) with no significant blood pressure rise at 0.5 mg :contentReference[oaicite:4]{index=4}.

Data from preclinical and clinical studies; tesofensine is not FDA‑approved in the U.S. for any indication.

What is tesofensine used for?
Designed for research on appetite regulation, metabolism, and obesity models.

How is it administered?
Delivered orally as capsules in lab or clinical settings.

How effective is it?
In human trials: 9–10% weight loss at 24 weeks (0.5 mg); up to ~14 kg loss at 48 weeks :contentReference[oaicite:5]{index=5}.

Side effects?
Mild-to-moderate—dry mouth, insomnia, nausea; slight heart rate increase; tolerability similar to placebo in trials :contentReference[oaicite:6]{index=6}.

Energy effects?
Beyond appetite suppression, may slightly increase energy expenditure via adrenergic activation :contentReference[oaicite:7]{index=7}.

For research use only—NOT intended for use in humans or animals, nor as a dietary supplement.

Safety: Handle using appropriate lab protocols and PPE; store in controlled environment ≤ –20 °C.

Regulatory Notice: These statements have not been evaluated by the FDA. Not intended to diagnose, treat, cure, or prevent any disease.

All products offered by TheraTide USA are strictly intended for research and development purposes only.

None of the statements on this website have been evaluated by the U.S. Food and Drug Administration. Our products are not intended to diagnose, treat, cure, or prevent any disease.

TheraTide USA is a research chemical supplier. We are not a compounding pharmacy or a chemical compounding facility as defined under Section 503A of the Federal Food, Drug, and Cosmetic Act.